Sutro Biopharma (STRO) Liabilities and Shareholders Equity (2017 - 2025)

Sutro Biopharma has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $173.8 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $173.8 million, down 55.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $967.3 million (down 44.14% YoY), and the FY2025 annual result was $173.8 million, down 55.11% from the prior year.
• Liabilities and Shareholders Equity came in at $173.8 million for Q4 2025 at Sutro Biopharma, down from $209.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $489.0 million in Q2 2024 to a low of $173.8 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $378.5 million (2021), against an average of $367.6 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 133.0% in 2021 and slumped 55.11% in 2025, its largest moves.
• Sutro Biopharma's Liabilities and Shareholders Equity stood at $341.4 million in 2021, then gained by 19.2% to $406.9 million in 2022, then gained by 15.68% to $470.7 million in 2023, then decreased by 17.74% to $387.2 million in 2024, then plunged by 55.11% to $173.8 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $173.8 million (Q4 2025), $209.7 million (Q3 2025), and $262.4 million (Q2 2025), per Business Quant data.